Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

150 results about "Thyroid hormones" patented technology

Thyroid hormones are two hormones produced and released by the thyroid gland, namely triiodothyronine (T₃) and thyroxine (T₄). They are tyrosine-based hormones that are primarily responsible for regulation of metabolism. T₃ and T₄ are partially composed of iodine. A deficiency of iodine leads to decreased production of T₃ and T₄, enlarges the thyroid tissue and will cause the disease known as simple goitre. The major form of thyroid hormone in the blood is thyroxine (T₄), which has a longer half-life than T₃. In humans, the ratio of T₄ to T₃ released into the blood is approximately 14:1. T₄ is converted to the active T₃ (three to four times more potent than T₄) within cells by deiodinases (5'-iodinase). These are further processed by decarboxylation and deiodination to produce iodothyronamine (T₁a) and thyronamine (T₀a). All three isoforms of the deiodinases are selenium-containing enzymes, thus dietary selenium is essential for T₃ production.

Hormone receptor functional dimers and methods of their use

InactiveUS7057015B1Enhance possibility of producingIncrease flexibilityFusion with DNA-binding domainSugar derivativesADAMTS ProteinsProtein Unit
The invention provides chimeric proteins having at least two functional protein units, each containing the dimerization domain of a member of the steroid / thyroid hormone nuclear receptor superfamily. The chimeric proteins can fold under crystallization conditions to form functional entities. The functional entities optionally contain a novel flexible peptide linker of variable lengths between at least two of the protein units. In a preferred embodiment, the linker is designed to be increased in increments of 12 amino acids each to aid in preparation of variant chimeric proteins. The DNA binding characteristics of the invention functional entities differ from those of wild-type complexes formed between “monomeric” receptors and their binding partners. Some functional entities, e.g. dimers expressed as fusion proteins, transactivate responsive promoters in a manner similar to wild-type complexes, while others do not promote transactivation and function instead essentially as constitutive repressors. The invention further provides nucleotide sequences encoding the invention chimeric proteins, cells containing such nucleotide sequences, and methods for using the invention chimeric proteins to modulate expression of one or more exogenous genes in a subject organism. In addition, isolated protein crystals suitable for x-ray diffraction analysis and methods for obtaining putative ligands for the invention chimeric proteins are provided.
Owner:SALK INST FOR BIOLOGICAL STUDIES

Antibody against human parathormone related peptides

Disclosed are an antibody against human para-thyroid-hormone-related protein, a DNA coding for the antibody, a recombinant vector containing the DNA, a transformant transformed with the recombinant vector, a method for preparation of the antibody, and uses of the antibody.
Owner:CHUGAI PHARMA CO LTD

Thyroid hormone analysis by mass spectrometry

Methods, systems and kits for the simultaneous or sequential analysis of one or more hormones by mass spectrometry are disclosed. The methods require minimal sample size and minimal preparation time. The methods include ionizing the hormones and analyzing the hormones by mass spectrometry. In addition, methods, systems and kits for the simultaneous or sequential analysis of thyroid hormones are disclosed including ionization of the thyroid hormones in the negative mode using an electrospray source.
Owner:GEORGETOWN UNIV

Method and composition for restoration of age related tissue loss in the face or selected areas of the body

A treatment method for restoring of age related tissue loss in the face or selected areas of the body is disclosed which includes injecting an injectable composition containing a growth factor and hyaluronic acid as a carrier into the dermis, the hypodermis, or both, in various areas of the face, or selected areas of the body of a person to stimulate collagen, elastin, or fat cell production, thereby restoring age related tissue loss in the face and selected areas of the body. Further disclosed is an injectable composition for restoring of age related tissue loss in the face and selected areas of the body, which contains a growth factor and hyaluronic acid as a carrier for providing time release of the growth factor into tissues. The growth factor can be insulin, insulin-like growth factor, thyroid hormone, fibroblast growth factor, estrogen, retinoic acid, or their combinations.
Owner:CELLHEALTH TECH

Thyroid Hormone Analogs and Methods of Use

Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.
Owner:NANOPHARM

Phosphate derivatives of pharmaceutical products

According to the invention, there is provided a complex of a pharmaceutical compound selected from the group consisting of opioids, hormones, anaethetics and chemotherapeutic agents comprising the reaction product of: (a) one or more phosphate derivatives of one or more opioids, steroid hormones, thyroid hormones, anaesthetics or chemotherapeutic agents having a phenolic, primary alcohol, secondary alcohol or tertiary hydroxyl group; and (b) a complexing agent selected from the group comprising amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these amino acids.
Owner:VITAL HEALTH SCIENCES PTY LTD

Thyroid hormone analogs and methods of use

Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.
Owner:NANOPHARM

Compositions and methods for treating alzheimer's disease and dementia

The present invention relates to a method of treating, preventing, or delaying the onset of Alzheimer's disease and / or dementia in mammals. More particularly, the invention relates to method of administration of compositions containing defined chemical species useful for treating, preventing, or delaying the onset of Alzheimer's disease and / or dementia in mammals. In some embodiments, a composition used in connection with such methods comprises one or more of 1) thyroid hormone and 2) cyclo(His-Pro) and a zinc salt. Such compositions may also be used to treat metabolic syndrome and cerebrovascular diseases.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS

Use of TGF-beta inhibitors to counteract pathologic changes in the level or function of steroid/thyroid receptors

The invention concerns the use of TGF-beta inhibitors to counteract a pathologic change in the expression level, activity and / or signaling of a receptor of the steroid-thyroid hormone receptor superfamily. In particular, the invention concerns a method for counteracting a pathologic change in a signal-transduction pathway involving a member of the steroid / thyroid hormone super-family, comprising administering to a mammalian subject in need an effective amount of a compound capable of inhibiting TGF-beta signaling through a TGF-beta receptor.
Owner:SCIOS

Thyroid hormone analogs and methods of use

Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.
Owner:NANOPHARM

Thyroid hormone analogs and methods of use

Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.
Owner:NANOPHARM

Pharmaceutical formulae for thyroid hormones and procedures for obtaining them

The present invention provides pharmaceutical formulation for thyroid hormones which allow safe and stable administration by mouth within the ambit of the narrow therapeutic index prescribed in the case of thyroid dysfunctions, as well as procedures for obtaining
Owner:ALTERGON

Combination of pilocarpin and methimazol for treating charcot-marietooth disease and related disorders

The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related peripheral neuropathies. More particularly, the invention relates to combined therapies for treating said disease by affecting simultaneously muscarinic receptor signaling and thyroid hormone pathway in a subject.
Owner:PHARNEXT

Novel methods of treating or preventing fibrotic lung diseases

The invention includes a method of preventing or treating a fibrotic lung disease in a subject, comprising administering to the subject a thyroid hormone by inhalation and / or aerosolization. The invention further comprises compositions and kits comprising compositions useful within the invention.
Owner:YALE UNIV

Oxygen-impervious packaging with optional oxygen scavenger, stabilized thyroid hormone compositions and methods for storing thyroid hormone pharmaceutical compositions

InactiveUS20060183804A1Improve performanceHead spaceBiocidePeptide/protein ingredientsThyroid hormonesLiothyronine Sodium
Novel packaging, methods of packaging and methods for storing thyroid hormone pharmaceutical compositions, such as levothyroxine (T4) sodium and liothyronine (T3) sodium, in reduced oxygen conditions for maintaining the stability and potency of the thyroid hormones during extended shelf life are provided.
Owner:KING PHARMA RES & DEV

Oxygen-impervious packaging with optional oxygen scavenger, stabilized thyroid hormone compositions and methods for storing thyroid hormone pharmaceutical compositions

The present invention provides stabilized thyroid hormone pharmaceutical compositions, and methods of packaging and storing thyroid hormone pharmaceutical compositions, such as levothyroxine (T4) sodium and liothyronine (T3) sodium, in reduced oxygen conditions for maintaining the stability and potency of the thyroid hormones during extended shelf life.
Owner:BRINKMAN KYLE R +2

Saccharide free, storage stable thyroid hormone active drug formulations and methods for their production

Embodiments of the present invention provide pharmaceutical compositions in unit dosage form that comprise a therapeutically effective amount of levothyroxine sodium; an antioxidant in an amount sufficient to stabilize the levothyroxine sodium against oxidation; an amount of an alditol sufficient to stabilize the levothyroxine sodium; and at least two excipients selected from a filler, a binder, and a lubricant. Such compositions are free of added monosaccharide, disaccharide, and an oligosaccharide and are storage stable.
Owner:FAMYGEN LIFE SCI INC

Differentiation of stem cells into thyroid tissue

ActiveUS20170027994A1Reduction amelioration of symptomRetain their thyroid functionPeptide/protein ingredientsCulture processThyroid hormonesThyroid Gland Tissue
Embodiments herein relate in vitro methods of stem cell differentiation into thyroid hormone producing cells and tissues, and methods of use of these cells.
Owner:TRUSTEES OF BOSTON UNIV +1

Concentrated Liquid Thyroid Hormone Composition

This invention is directed generally to a liquid pharmaceutical composition comprising at least one thyroid hormone (particularly a composition further comprising at least one cyclodextrin compound), a process for making such a composition and a method of using such a composition to treat a condition associated with impaired thyroid hormone function.
Owner:INTERVET INT BV

Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use

The present invention relates to sulfonic acid containing compounds of formula IB, in which G, R1, R3 and T are as defined in the claims, that bind to thyroid receptors in the liver. Activation of these receptors results in modulation of gene expression of genes regulated by thyroid hormones. The compounds can be used to treat diseases and disorders including metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome X and diabetes.
Owner:METABASIS THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products